1 U.S. lawmaker has disclosed 1 Arcutis Biotherapeutics, Inc. - trade under the STOCK Act — 1 buy and 0 sells in 2022. Congress has been net buyers of ARQT, and their disclosed buys are up 30.2% versus the latest close.
*Notional-weighted price return on lawmakers' disclosed buys of ARQT, marked to the latest close — per-share (share counts aren't disclosed).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2022-06-15 | Hon. Josh Gottheimer | BUY | $1K–$15K | $20.55 | $26.76 2026-06-29 | +30.2% |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
1 member of the U.S. House and Senate has disclosed Arcutis Biotherapeutics, Inc. - transactions under the STOCK Act — 1 purchase and 0 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
Notional-weighted, lawmakers' disclosed ARQT buys are up 30.2% versus the latest close of $26.76. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded ARQT and how it performed.